Seeking Alpha

Celgene's (CELG +1.6%) Abraxane breast cancer treatment for patients with metastatic melanoma...

Celgene's (CELG +1.6%) Abraxane breast cancer treatment for patients with metastatic melanoma met its primary endpoint of "progression-free survival" in a Phase III trial that compared the medicine with acarbazine chemotherapy. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)